LEPABE-Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal.
ALiCE-Associate Laboratory in Chemical Engineering, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal.
Int J Mol Sci. 2023 May 20;24(10):9030. doi: 10.3390/ijms24109030.
Antimicrobial resistance (AMR) is considered one of the greatest threats to global health. Methicillin-resistant (MRSA) remains at the core of this threat, accounting for about 90% of infections widespread in the community and hospital settings. In recent years, the use of nanoparticles (NPs) has emerged as a promising strategy to treat MRSA infections. NPs can act directly as antibacterial agents via antibiotic-independent activity and/or serve as drug delivery systems (DDSs), releasing loaded antibiotics. Nonetheless, directing NPs to the infection site is fundamental for effective MRSA treatment so that highly concentrated therapeutic agents are delivered to the infection site while directly reducing the toxicity to healthy human cells. This leads to decreased AMR emergence and less disturbance of the individual's healthy microbiota. Hence, this review compiles and discusses the scientific evidence related to targeted NPs developed for MRSA treatment.
抗微生物药物耐药性 (AMR) 被认为是对全球健康的最大威胁之一。耐甲氧西林金黄色葡萄球菌 (MRSA) 仍然是这一威胁的核心，约占社区和医院环境中广泛存在的感染的 90%。近年来，纳米颗粒 (NPs) 的应用作为一种治疗 MRSA 感染的有前途的策略而出现。NPs 可以通过非抗生素依赖性活性直接作为抗菌剂发挥作用，和/或充当药物递送系统 (DDS)，释放负载的抗生素。然而，将 NPs 引导至感染部位对于有效治疗 MRSA 至关重要，以便将高浓度的治疗剂递送至感染部位，同时直接降低对健康人细胞的毒性。这导致 AMR 的出现减少，个体健康微生物组的干扰减少。因此，本综述汇编并讨论了与针对 MRSA 治疗开发的靶向 NPs 相关的科学证据。
